The biopharmaceutical company developed VTAMA cream as a once-daily and steroid-free topical cream for both acute treatment and long-term management of AD.
Today, Dermavant Sciences announced they’ve submitted a supplemental new drug application (sNDA) to the FDA for VTAMA (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) for adults and children 2-years-old or older.
The biopharmaceutical company developed VTAMA cream as a novel, aryl hydrocarbon receptor agonist in development as a once-daily, steroid-free, topical cream for both acute treatment and long-term management of AD.
VTAMA cream, 1% is currently approved for the topical treatment of plaque psoriasis in adults in the United States and is the same strength and formulation studied in the ADORING phase 3 development program and included in the sNDA submission for atopic dermatitis, according to a news release by Dermavant.
AD, also known as a form of eczema, is one of the most common inflammatory skin diseases, impacting approximately 16.5 million adults and more than 9.6 million children in the United States. More than 85% of people with AD experience itching every day, making it the most common and burdensome symptom, Dermavant said.
In the ADORING trials, VTAMA improved skin conditions, with more patients achieving clear or nearly clear skin compared with those using a placebo. The cream also helped reduce itching, a common symptom of eczema. The trials included patients 12 and older, and the cream demonstrated good safety with mostly mild side effects.
VTAMA was approved in May 2022 for the treatment of plaque psoriasis in adults. In October 2023, Dermavant announced positive results from its phase 4, open-label clinical trial of VTAMA treatment of intertriginous plaque psoriasis (iPsO) in adults. Intertriginous plaque psoriasis inflammatory condition of skin folds
Announced at the 43rd Annual Fall Clinical Dermatology Conference in Las Vegas, the data showed that 82.8% of adult patients saw significant improvement, with clear or almost clear skin, and at least a two-grade enhancement from the start of the trial by Week 12.
The treatment showed rapid efficacy, with success seen as early as 2 weeks and a median time of 6 weeks. By Week 12, 65.5% of patients had completely cleared affected areas.
Additionally, 75% experienced a notable reduction in itch, a common symptom, and reported improved quality of life. The treatment demonstrated safety and tolerability with no new concerns identified during the 12-week trial.
Ruxolitinib Cream Proves Safe for Young Children with Atopic Dermatitis
July 22nd 2024These results were found in the TRuE-AD3 study that was presented at the Society for Pediatric Dermatology meeting earlier this month, revealing the latest round of data collected in the TRuE-AD1 and TRuE-AD2 series of studies.
Read More
Study Reveals Severe Impact of Atopic Dermatitis on Women's Quality of Life and Reproductive Health
July 15th 2024Although AD is a common condition, it’s impact on sexual function and reproductive health is not well understood. In addition, many women with AD are undertreated during pregnancy due to concerns about medication side effects.
Read More
High Sodium Intake Associated to Increased Risk of Severe Atopic Dermatitis
June 20th 2024Researchers who conducted the study, of the Universities of California in San Francisco and Berkley, suggest that cutting down on sodium could be a more cost-effective and low-risk way to help manage AD.
Read More
Highly Contagious and Hard-to-Treat Fungal Skin Infections Are Emerging, Experts Warn
June 6th 2024Experts are urging healthcare providers to be aware of these two new forms of ringworm or jock itch, known as Trichophyton mentagrophytes type VII (TMVII) and Trichophyton indotineae or T. indotineae.
Read More